The future of healthcare is in the data.
There is tremendous use for data and AI in many facets of healthcare, and one area in which the latest data technology is creating improvements is in the diagnosis of developmental health in early childhood.
Historically, diagnosing developmental delay such as autism has been a complex, time-consuming process, sometimes taking months or even years without a definitive answer.
Cognoa’s Canvas Dx, the first FDA authorized diagnostic device for autism, helps healthcare providers to diagnose or rule out autism in young children. Using AI to analyze a large volume of data from multiple sources in real time, Canvas Dx can shorten the time to diagnosis by potentially up to a year and a half earlier than today’s average.
Canvas Dx also provides improved access to autism diagnosis, which can help facilitate life-changing early interventions for children with developmental delay. This one-of-a-kind diagnostic can also help rule out autism, which can clear the way for other interventions.
Powering the AI behind Canvas Dx is a platform called Lakehouse, developed by data technology pioneers Databricks.
“With the help of Databricks Lakehouse, this critical data, analytics and AI can potentially shorten the time to diagnosis for many children,” said Valerie Jenkins, Head of Communications at Cognoa. “We take in huge amounts of unstructured and structured data, standardize it, and run machine learning models that help inform a provider’s diagnosis.”
Watch this video about how Cognoa uses Databricks Lakehouse within our underlying CanvasDx data science processes:
You can also read more about how Canvas Dx utilizes the Databricks Lakehouse platform in this case study:
“Cognoa is not only a pediatric behavioral health company — we’re a data and AI company. We want to improve how behavioral health conditions are diagnosed and treated, and, with the help of Databricks Lakehouse, we’re just getting started,” concluded Jenkins.